Novo Sees Generic Ozempic Delayed in China Until Next Year

· Financial Post

(Bloomberg) — Novo Nordisk A/S expects generic Ozempic to be delayed in China until next year, a positive step for the drugmaker as it battles to keep its share of the global obesity market.  Read More

Visit saltysenoritaaz.com for more information.

Read full story at source